Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
6.90
-0.41 (-5.61%)
At close: Nov 20, 2026, 4:00 PM EST
6.99
+0.09 (1.25%)
After-hours: Nov 20, 2026, 7:59 PM EST
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $14.1. The average 1-year stock price forecast is 104.35% higher than the current stock price, while the lowest is $7.00 (+1.45%) and the highest is $20 (+189.86%).
Price Target: $14.1 (+104.35%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +189.86% | Nov 11, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $8 → $12 | Buy | Maintains | $8 → $12 | +73.91% | Nov 6, 2026 |
| Barclays | Barclays | Buy Maintains $18 → $19 | Buy | Maintains | $18 → $19 | +175.36% | Nov 6, 2026 |
| UBS | UBS | Hold Reiterates $7 → $8 | Hold | Reiterates | $7 → $8 | +15.94% | Nov 3, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +30.43% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
418.65M
from 263.50M
Increased by 58.88%
Revenue Next Year
594.40M
from 418.65M
Increased by 41.98%
EPS This Year
-0.38
from -1.09
EPS Next Year
-0.13
from -0.38
EPS and Forward PE are based on non-GAAP adjusted numbers.